{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024868","form_type":"8-K","ticker":"GNLX","cik":"0001231457","company_name":"GENELUX Corp","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.364530+00:00","generated_at":"2026-06-13T06:16:27.096915+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genelux: Olvi-Vec estimated billion+ US market; interim data in recurrent NSCLC expected mid-2024","bullets":["Olvi-Vec estimated to represent more than $1 billion annual US market opportunity.","Interim data from systemic Olvi-Vec trials in recurrent NSCLC expected as early as mid-2024.","Corporate presentation outlines pipeline and commercial potential for lead candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024868","json":"https://secwatch.observer/filing/0001493152-23-024868.json","markdown":"https://secwatch.observer/filing/0001493152-23-024868.md","text":"https://secwatch.observer/filing/0001493152-23-024868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1231457/000149315223024868/0001493152-23-024868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1231457/000149315223024868/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:16:27.096915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}